Copyright © Inderes 2011 - present. All rights reserved.
  • Seneste
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Udbyttekalender
    • Research
    • Artikler
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team

Paxman

57,00 SEK

0,00 %

Mindre end 1K følgere

PAX

First North Stockholm

Medical Equipment & Services

Health Care

Oversigt
Finansielt overblik og estimater
Ejerskab
Investorkonsensus
Sammenligne
0,00 %
-10,94 %
-27,48 %
-31,82 %
-13,11 %
-12,31 %
+30,43 %
+148,91 %
+422,94 %

Paxman is active in scalp cooling, which is used for patients undergoing chemotherapy. The company's product Paxman Scalp Cooler is used to minimize hair loss in patients during treatment. The Scalp Cooler is a freestanding, mobile and electrically powered cooling unit that cools the patient's scalp via a cooling cap. Paxman was founded in 1996 and is headquartered in Karlshamn.

Læs mere
Markedsværdi
1,33 mia. SEK
Aktieomsætning
2,97 mio. SEK
Omsætning
253,01 mio.
EBIT %
13,24 %
P/E
27,01
Udbytteafkast, %
-
Omsætning og EBIT-margin

Omsætning mio.

EBIT-% (adj.)

EPS og udbytte

EPS (adj.)

Udbytte %

Finanskalender
27.2
2026

Årsrapport '25

21.5
2026

Delårsrapport Q1'26

22.5
2026

Generalforsamling '26

Alle
Selskabsmeddelelser
ViserAlle indholdstyper
Pressemeddelelse27.11.2025, 16.59

DNB Carnegie Access: Paxman: Key highlights from Capital Markets Day

Paxman
Pressemeddelelse24.11.2025, 18.45

Correction: Further updated Information on OPPS Reimbursement

Paxman
Pressemeddelelse24.11.2025, 17.41

Correction: Updated Information on OPPS Reimbursement

Paxman

Bliv en del af Inderes community

Gå ikke glip af noget - opret en konto og få alle de mulige fordele

Inderes konto
Følgere og notifikationer om fulgte virksomheder
Analytikerkommentarer og anbefalinger
Værktøj til at sammenligne aktier og andre populære værktøjer
Opret konto
Pressemeddelelse24.11.2025, 17.00

DNB Carnegie Access: Paxman: CMS Final Rule landed neutral – long-term story intact

Paxman
Pressemeddelelse24.11.2025, 15.45

Paxman announces that CMS has finalized the 2026 Medicare payment rates for mechanical scalp cooling under the Hospital Outpatient and Physician Fee Schedule.

Paxman
Pressemeddelelse17.11.2025, 13.22

DNB Carnegie Access: Paxman: Margin pressure as expected, outlook still good – Q3 review

Paxman
Pressemeddelelse17.11.2025, 08.28

Redeye: Paxman Q3 (Review) - Softer sales than expected, but outlook remains strong

Paxman
Pressemeddelelse14.11.2025, 07.03

DNB Carnegie Access: Paxman: Meets our expectations on profitability – Q3 initial comment

Paxman
Selskabsmeddelelse14.11.2025, 06.00

PAXMAN publishes its interim report for Q3 2025

Paxman
Pressemeddelelse7.11.2025, 10.15

Invitation: Live Presentation with CEO Richard Paxman – Q3 2025

Paxman
Pressemeddelelse24.10.2025, 08.00

Reminder- PAXMAN invitation to Capital Market Day

Paxman
Pressemeddelelse20.10.2025, 15.42

DNB Carnegie Access: Paxman: First full quarter post-Dignitana deal – Q3 preview

Paxman
Pressemeddelelse20.10.2025, 12.01

Paxman announces progress of its Clinical Trial for Chemotherapy Induced Peripheral Neuropathy, with latest data presented at EONS18 Conference part of ESMO® Congress 2025

Paxman
Pressemeddelelse17.10.2025, 13.50

PAXMAN announces the acceptance of the Paxman Limb Cryocompression System (PLCS) into the FDA’s Safer Technologies Program (STeP).

Paxman
Pressemeddelelse9.10.2025, 08.00

PAXMAN invitation to Capital Market Day

Paxman
Pressemeddelelse23.9.2025, 19.05

PAXMAN's founder is reducing his shareholding

Paxman
Pressemeddelelse21.8.2025, 08.38

Redeye: Paxman Q2 - Nothing spectacular, but in the right direction

Paxman
Pressemeddelelse21.8.2025, 07.41

DNB Carnegie Access: Paxman: Resilient growth, but integration weighs on margins

Paxman
Pressemeddelelse20.8.2025, 09.35

DNB Carnegie Access: Paxman: Recording from Earnings Call Q2(25)

Paxman
Pressemeddelelse20.8.2025, 08.30

See Richard Paxman comment on the Q2 report

Paxman
Find os på de sociale medier
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Vores team
  • Karriere
  • Inderes som en investering
  • Tjenester for børsnoterede virksomheder
Vores platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.